Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Efficacy and Safety Study of BG00012 With Methotrexate in Patients With Active Rheumatoid Arthritis
- First Posted Date
- 2008-12-18
- Last Posted Date
- 2013-09-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 153
- Registration Number
- NCT00810836
- Locations
- 🇸🇰
Research Site, Piestany, Slovakia
Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Drug: FCR
- First Posted Date
- 2008-12-03
- Last Posted Date
- 2015-10-02
- Lead Sponsor
- Biogen
- Target Recruit Count
- 40
- Registration Number
- NCT00801060
- Locations
- 🇺🇸
University of Florida/Pulmonary, Critical Care & Sleep Medicine, Gainesville, Florida, United States
🇺🇸University of Miami Miller School of Medicine, Miami, Florida, United States
🇬🇧Research Site, Bath, Avon, United Kingdom
Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-α Therapy
- Conditions
- Crohn's Disease
- First Posted Date
- 2008-12-03
- Last Posted Date
- 2016-06-16
- Lead Sponsor
- Biogen
- Registration Number
- NCT00801125
Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) Patients
- Conditions
- Multiple Sclerosis
- Interventions
- Drug: BG9418 (interferon beta 1-a)
- First Posted Date
- 2008-11-04
- Last Posted Date
- 2014-05-07
- Lead Sponsor
- Biogen
- Target Recruit Count
- 3
- Registration Number
- NCT00784836
- Locations
- 🇺🇸
Henry Ford Hospital, Detroit, Michigan, United States
🇺🇸MS Center at Texas Neurology, Dallas, Texas, United States
BIIB023 (Anti-TWEAK) in Subjects With Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- Other: Placebo (sterile normal saline)
- First Posted Date
- 2008-10-13
- Last Posted Date
- 2013-09-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 53
- Registration Number
- NCT00771329
- Locations
- 🇺🇸
Research Site, Oklahoma City, Oklahoma, United States
🇷🇺Research Centre, Yaroslavl, Russian Federation
A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a
- Conditions
- Relapsing-remitting Multiple Sclerosis
- Interventions
- First Posted Date
- 2008-10-10
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Biogen
- Registration Number
- NCT00771043
Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML)
- First Posted Date
- 2008-09-04
- Last Posted Date
- 2014-07-31
- Lead Sponsor
- Biogen
- Target Recruit Count
- 37
- Registration Number
- NCT00746941
- Locations
- 🇪🇸
Research Site, Madrid, Spain
Oral Tonapofylline (BG9928) in Patients With Heart Failure and Renal Insufficiency
- Conditions
- Renal InsufficiencyHeart Failure
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-09-03
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- Biogen
- Target Recruit Count
- 34
- Registration Number
- NCT00745316
A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State
- First Posted Date
- 2008-09-01
- Last Posted Date
- 2015-02-10
- Lead Sponsor
- Biogen
- Target Recruit Count
- 20
- Registration Number
- NCT00744679
- Locations
- 🇺🇸
Research Site, Latham, New York, United States
Administration of BIIB028 to Subjects With Solid Tumors
- Conditions
- Advanced Solid Tumors
- First Posted Date
- 2008-07-31
- Last Posted Date
- 2017-01-09
- Lead Sponsor
- Biogen
- Target Recruit Count
- 43
- Registration Number
- NCT00725933
- Locations
- 🇺🇸
Research Site, Houston, Texas, United States